Adv Healthc Mater

1. YIN Y, Qin Z, Zhou H, Wu Y, et al
   Ultrasound Responsive Mn/Se-Nanozyme as PANoptosis Initiators for Bladder Cancer Immunotherapy.
   Adv Healthc Mater. 2026 Feb 3:e04808. doi: 10.1002/adhm.202504808.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

2. KONG L, Yang G, Weng B, Wen Z, et al
   Early Detection of Chemotherapy-Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium ((2)H) Metabolic Imaging: in Vitro and in Vivo Assessments.
   Adv Sci (Weinh). 2026;13:e14614.
   

   >> Share

   
   

   
   Afr Health Sci

3. LIU N, Xing L, Chen H, Chen S, et al
   Sequential dilatation of two balloons and double D-J stents for therapy of ureteroenteral anastomotic stricture in patients following radical cystectomy and Bricker urinary diversion.
   Afr Health Sci. 2025;25:334-342.
   

   >> Share

   
   

   
   Am J Clin Pathol

4. NABIYOUNI F, Chiou PZ
   Enhancing urine cytopathology with artificial intelligence: a systematic review.
   Am J Clin Pathol. 2026;165:aqaf135.
   

   >> Share

   
   

   
   Ann Surg Oncol

5. LIU Q, Lu X, He C, Chen J, et al
   A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
   Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19122.
   

   >> Share

   
   
6. WANG Y, Guo S, Zeng J, Feng W, et al
   Prognostic Significance of Lymph Node Ratio for Overall Survival in Patients with Lymph Node-Positive Bladder Cancer Post-Radical Cystectomy and Chemotherapy: A Multicenter Cohort Analysis.
   Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19090.
   

   >> Share

   
   
7. HAJIME T, Shiota M, Matsumoto T, Mutaguchi J, et al
   ASO Author Reflections: Tumor Laterality as a Key Determinant of Pelvic Lymph Node Dissection Strategy in Bladder Cancer.
   Ann Surg Oncol. 2026 Feb 3. doi: 10.1245/s10434-026-19200.
   

   >> Share

   
   
8. MEHMUD I, Zhang Y, Wu S, Zhang S, et al
   Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer.
   Ann Surg Oncol. 2026 Feb 6. doi: 10.1245/s10434-025-19064.
   

   >> Share

   
   

   
   Appl Immunohistochem Mol Morphol

9. HSIEH YC, Li CF, Ho CH, Huang SK, et al
   Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma.
   Appl Immunohistochem Mol Morphol. 2026 Feb 5. doi: 10.1097/PAI.0000000000001307.
   

   >> Share

   
   

   
   Asian J Endosc Surg

10. MORIKAWA T, Hamamoto S, Tasaki Y, Ishikawa D, et al
    Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.
    Asian J Endosc Surg. 2026;19:e70248.
    

    >> Share

    
    
11. YOKOYAMA T, Kobayashi H, Horiguchi A, Miyai K, et al
    A Case of Primary Bladder Neuroendocrine Carcinoma With Urethral Invasion Following Radical Prostatectomy.
    Asian J Endosc Surg. 2026;19:e70251.
    

    >> Share

    
    

    
    Biopreserv Biobank

12. MOJICA W, Izydorczak A, Wood T, Hsu J, et al
    A Novel Method to Generate Analyte-Specific Specimens for Multi-Omic Studies of Primary Bladder Cancer.
    Biopreserv Biobank. 2026 Feb 6:19475535251394594. doi: 10.1177/19475535251394594
    

    >> Share

    
    

    
    BMC Cancer

13. OSAKA K, Kishida T, Umemoto S, Karashima T, et al
    Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
    BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
    

    >> Share

    
    
14. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
    BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
    

    >> Share

    
    

    
    BMJ Oncol

15. SOMA T, Takemura K, Toide M, Ito M, et al
    Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure: a systematic review.
    BMJ Oncol. 2026;5:e000753.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

16. BOURGI A, Rusch E, Bruyere F
    Water-Related Exposures And Bladder Cancer Risk: A Comprehensive Epidemiological Review.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Invest

17. WANG J, Zhao X, Jiang XL, Liu G, et al
    Construction and Validation of a Prognostic Survival Prediction Model for NMIBC Patients Undergoing Radical Cystectomy.
    Cancer Invest. 2026;44:156-173.
    

    >> Share

    
    

    
    Cancer Lett

18. YU K, Sun J, Zhang J, Shi Y, et al
    Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer.
    Cancer Lett. 2026;642:218282.
    

    >> Share

    
    

    
    Cancer Metastasis Rev

19. ZHOU J, Jiang X, Liu Q, Xia HA, et al
    PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.
    Cancer Metastasis Rev. 2026;45:7.
    

    >> Share

    
    

    
    Cell Mol Life Sci

20. ZHANG H, Liu Y, Huang W, Li Y, et al
    Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.
    Cell Mol Life Sci. 2026 Feb 3. doi: 10.1007/s00018-026-06083.
    

    >> Share

    
    

    
    Cell Rep

21. XU G, Li Y, Peng S, Zhao W, et al
    Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer.
    Cell Rep. 2026;45:116941.
    

    >> Share

    
    

    
    Cell Signal

22. SONG T, He W, Yuan Q, Xia S, et al
    ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance.
    Cell Signal. 2026 Feb 4:112398. doi: 10.1016/j.cellsig.2026.112398.
    

    >> Share

    
    

    
    Clin Cancer Res

23. GUERCIO BJ, Pietzak EJ, Ravichandran V, Chen JF, et al
    Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
    Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-3771.
    

    >> Share

    
    

    
    Commun Biol

24. KIELBIK A, Hellwich E, Bahlinger V, Sowa P, et al
    Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells.
    Commun Biol. 2025;9:153.
    

    >> Share

    
    

    
    Comput Methods Programs Biomed

25. ZHAO J, Zhao J, Huang W, Lin W, et al
    Decoding metabolic reprogramming heterogeneity across bladder cancer stages using single-cell and spatial multi-omics approaches.
    Comput Methods Programs Biomed. 2026;277:109261.
    

    >> Share

    
    

    
    Curr Drug Targets

26. HARLE V, Agrawal YO
    Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.
    Curr Drug Targets. 2025;26:903-920.
    

    >> Share

    
    

    
    Curr Issues Mol Biol

27. AY A, Alkanli N, Atli E, Gurkan H, et al
    Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression.
    Curr Issues Mol Biol. 2025;48:53.
    

    >> Share

    
    

    
    Curr Opin Urol

28. LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Montironi R, et al
    Sarcomatoid urothelial carcinoma: advances and challenges.
    Curr Opin Urol. 2026;36:147-154.
    

    >> Share

    
    
29. COMPERAT E
    Biomarkers and testing in pathology.
    Curr Opin Urol. 2026;36:212-216.
    

    >> Share

    
    
30. ERTOY-BAYDAR D
    Histologic subtypes of urothelial carcinoma: an update.
    Curr Opin Urol. 2026;36:138-146.
    

    >> Share

    
    
31. REIS H, Szarvas T, Paner GP
    Urachal cancer: a clinical, diagnostic, and therapeutic update.
    Curr Opin Urol. 2026;36:155-160.
    

    >> Share

    
    

    
    Drugs

32. RIAZ IB, Humayun MA, Khaki AR, Hussain SA, et al
    Treatment Sequencing in Advanced Urothelial Cancer.
    Drugs. 2026;86:203-215.
    

    >> Share

    
    

    
    Environ Sci Technol

33. WANG Y, Ni H, Dong S, Shang Y, et al
    Environmental Dose MEOHP Promotes Bladder Cancer Progress through Hybrid EMT Mechanism: Based on the Adverse Outcome Pathway.
    Environ Sci Technol. 2026 Feb 6. doi: 10.1021/acs.est.5c08003.
    

    >> Share

    
    

    
    Eur Rev Med Pharmacol Sci

34. DE FELICE M, Tammaro M, Caterino M, Nacca V, et al
    Fulminant Fournier gangrene in bladder cancer: case report and review of the literature.
    Eur Rev Med Pharmacol Sci. 2026;30:46-50.
    

    >> Share

    
    

    
    Eur Urol

35. BABJUK M
    Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
    Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
36. PICHLER R, Subiela JD, Guerrero-Ramos F
    Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
    Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
37. HAYNE D, Zhang AY, Thomas H, Krieger L, et al
    Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
    Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
38. GABRIEL PE, Xylinas E
    Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
    Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
39. TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
    Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
40. MYERS AA, Talwar R, Duan Z, Hensley P, et al
    Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
    Eur Urol. 2026;89:151-162.
    

    >> Share

    
    

    
    Eur Urol Focus

41. PYRGIDIS N, Schulz GB, Scilipoti P, Pellegrino F, et al
    The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis.
    Eur Urol Focus. 2026;12:88-95.
    

    >> Share

    
    
42. CHATZKEL J, Linscott J, Daniel Grass G, Li R, et al
    Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies.
    Eur Urol Focus. 2026;12:38-40.
    

    >> Share

    
    
43. FILON M, Schmidt B
    The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer.
    Eur Urol Focus. 2026;12:34-37.
    

    >> Share

    
    

    
    Eur Urol Oncol

44. ROBBRECHT DGJ, Salhi Y, Martens JWM, Aarts MJB, et al
    Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.
    Eur Urol Oncol. 2026;9:7-11.
    

    >> Share

    
    
45. TEOH JY, Bracco FM, Wong JH, Liu AQ, et al
    A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial.
    Eur Urol Oncol. 2026;9:111-115.
    

    >> Share

    
    

    
    Front Immunol

46. NING W, Chang P, Zheng J, Chen W, et al
    Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.
    Front Immunol. 2026;16:1684597.
    

    >> Share

    
    

    
    Front Mol Biosci

47. ZHANG M, Lin L, Xu H, Su X, et al
    A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer.
    Front Mol Biosci. 2026;12:1722809.
    

    >> Share

    
    

    
    Int Immunopharmacol

48. JIN H
    Comment on "adjuvant bacillus Calmette-Gu'erin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study".
    Int Immunopharmacol. 2026;173:116312.
    

    >> Share

    
    

    
    Int J Hyperthermia

49. MIKHAIL AS, Gurram S, Valera VA, Haemmerich D, et al
    Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.
    Int J Hyperthermia. 2026;43:2615462.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

50. MAK KS, Efstathiou JA
    Tipping the Scales for Bladder Cancer: Weighing Differences in Quality of Life After Cystectomy Versus Trimodality Therapy.
    Int J Radiat Oncol Biol Phys. 2026;124:651-653.
    

    >> Share

    
    

    
    Int J Surg

51. WANG Z, He W, Wang M, Hua M, et al
    Integrated multicenter single-cell atlas of bladder cancer reveals tumor heterogeneity associated with immunotherapy.
    Int J Surg. 2026 Feb 3. doi: 10.1097/JS9.0000000000003830.
    

    >> Share

    
    

    
    Int J Urol

52. ABE Y, Taoka R, Kaji A, Harada S, et al
    Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
    Int J Urol. 2026;33:e70365.
    

    >> Share

    
    

    
    J Endourol

53. MENG X, Su CY, Yang Z
    Editorial Comment on: "Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative Analysis and Optimization Study of Multiple Large Language Models" by Li et al.
    J Endourol. 2026 Feb 2:8927790251387369. doi: 10.1177/08927790251387369.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

54. CHEN K, Su H, Pei F, Chen X, et al
    KNTC1 initiates a KNTC1/E2F8/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer.
    J Exp Clin Cancer Res. 2026 Feb 4. doi: 10.1186/s13046-026-03651.
    

    >> Share

    
    

    
    J Immunother Cancer

55. SHEN C, Liu C, Hu D, Ge H, et al
    Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
    J Immunother Cancer. 2026;14:e013809.
    

    >> Share

    
    

    
    J Pharm Anal

56. WANG X, Jin L, Zou X, Zhu A, et al
    ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.
    J Pharm Anal. 2026;16:101519.
    

    >> Share

    
    

    
    J Surg Oncol

57. MANOHARAN M, Raja Iyub MJ, Zhang Y, Prabhakar P, et al
    Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy.
    J Surg Oncol. 2026;133:226-232.
    

    >> Share

    
    

    
    Mater Today Bio

58. WANG Y, Yuan H, Zhang Y, Zhang Y, et al
    Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer.
    Mater Today Bio. 2026;37:102835.
    

    >> Share

    
    

    
    Medicine (Baltimore)

59. JIANG M, Sun C, Wang B, Huang Q, et al
    Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study.
    Medicine (Baltimore). 2026;105:e47378.
    

    >> Share

    
    

    
    medRxiv

60. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.
    medRxiv [Preprint]. 2026 Jan 30:2026.01.27.26344939.
    

    >> Share

    
    
61. GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
    Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
    medRxiv [Preprint]. 2026 Jan 16:2026.01.14.26344033.
    

    >> Share

    
    

    
    Mol Cancer

62. DU A, Zhou Y, Deng X, Yuan D, et al
    DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6.
    Mol Cancer. 2026 Jan 30. doi: 10.1186/s12943-025-02560.
    

    >> Share

    
    

    
    Mol Ther

63. CHEN Z, Chen X, Xie R, Huang M, et al
    DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
    Mol Ther. 2026 Jan 30:S1525-0016(26)00036-5. doi: 10.1016/j.ymthe.2026.
    

    >> Share

    
    

    
    Mol Ther Oncol

64. VAN DE MERBEL AF, van der Mark MH, Hensen LCM, van den Wollenberg DJM, et al
    Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models.
    Mol Ther Oncol. 2026;34:201128.
    

    >> Share

    
    

    
    Nat Rev Urol

65. RAGGI D, Crupi E, Pederzoli F, Martini A, et al
    HER2 and urothelial carcinoma: current understanding and future directions.
    Nat Rev Urol. 2026;23:110-132.
    

    >> Share

    
    
66. WU K, Liu X, Zhang J, Wang X, et al
    Mechanisms and implications of epithelial cell plasticity in the bladder.
    Nat Rev Urol. 2026;23:70-88.
    

    >> Share

    
    
67. DAY E, Bizzarri FP, Mackenzie C, Szabados B, et al
    Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.
    Nat Rev Urol. 2026 Jan 30. doi: 10.1038/s41585-026-01124.
    

    >> Share

    
    

    
    Oncogene

68. WANG J, Wang J, Meng L, Wang X, et al
    Interstitial cystitis-related gene CCDC8 accelerates tumorigenesis by participating in CUL7-mediated degradation of P53 in bladder cancer.
    Oncogene. 2026 Feb 5. doi: 10.1038/s41388-026-03688.
    

    >> Share

    
    

    
    Oncol Res Treat

69. HILSER T, Darr C, Bedke J, Ivanyi P, et al
    Treatment of Advanced or Metastatic Urothelial Cancer.
    Oncol Res Treat. 2026;49.
    

    >> Share

    
    

    
    Oncology

70. CHEN J, Fu S, Yu J, Tang Q, et al
    Modified Glasgow prognostic score as a marker for predicting outcomes in patients with either bladder and prostate cancer : A systematic review and meta-analysis.
    Oncology. 2025 Mar 28:1-20. doi: 10.1159/000545001.
    

    >> Share

    
    
71. TAKADA H, Ikeda M, Tanaka R, Samejima N, et al
    Prognostic effect of preoperative albumin-to-globulin ratio in patients with non-metastatic bladder cancer undergoing radical cystectomy.
    Oncology. 2026 Feb 6:1-20. doi: 10.1159/000550892.
    

    >> Share

    
    

    
    Pan Afr Med J

72. EL OMRI G, Houssaini OI, Rachid M, Houry Y, et al
    Non-functional bladder paraganglioma in a young patient: conservative management by transurethral resection and diagnostic challenges.
    Pan Afr Med J. 2025;52:105.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

73. KATSUMATA Y, Yamamoto S, Iwata H, Kuroiwa H, et al
    Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study.
    Photodiagnosis Photodyn Ther. 2026;57:105319.
    

    >> Share

    
    
74. YAMAMOTO S, Fukata S, Shimasaki S, Kurano Y, et al
    Clinical Outcomes Following Transurethral Laser Ablation with Topical Versus General or Spinal Anesthesia for Non-Muscle-Invasive Bladder Cancer: A Japanese Single-Center Pilot Study.
    Photodiagnosis Photodyn Ther. 2026 Jan 31:105376.
    

    >> Share

    
    

    
    PLoS One

75. FENG C, Chen G, Shu Y, Chen J, et al
    Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
    PLoS One. 2026;21:e0342162.
    

    >> Share

    
    

    
    Radiol Case Rep

76. YOUSSEF M, Nasseredine B, Amine Z, Amine S, et al
    Psoas metastasis mimicking abscess in untreated muscle-invasive bladder cancer: A diagnostic pitfall.
    Radiol Case Rep. 2026;21:1554-1558.
    

    >> Share

    
    

    
    Research (Wash D C)

77. LIU Z, Zhou C, Xu W, Zhang D, et al
    Polyarginine Peptide R11-Actin Interaction Induces a Domino Effect on Cytoskeleton Remodeling to Suppress Bladder Cancer Metastasis.
    Research (Wash D C). 2026;9:1109.
    

    >> Share

    
    

    
    Sci Rep

78. ZARZYCKA M, Kotula-Balak M, Gil D
    Inhibiting autophagy enhances anti-cancer properties of sulforaphane.
    Sci Rep. 2026;16:5296.
    

    >> Share

    
    
79. TANG X, Liu L, Gao M, Duan P, et al
    Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer.
    Sci Rep. 2026 Feb 3. doi: 10.1038/s41598-026-38219.
    

    >> Share

    
    

    
    Support Care Cancer

80. ZHANG M, Zhou Y
    Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study.
    Support Care Cancer. 2026;34:151.
    

    >> Share

    
    

    
    Tissue Cell

81. NIHARIKA, Tripathi S, Singhai A, Goel A, et al
    Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients.
    Tissue Cell. 2026;99:103240.
    

    >> Share

    
    

    
    Transl Oncol

82. LABROY M, Chabaud S, Durand M, Fourquaux I, et al
    Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.
    Transl Oncol. 2026;65:102687.
    

    >> Share

    
    

    
    Tumour Virus Res

83. LI D, Lu J, Zhu R, Sun X, et al
    Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest.
    Tumour Virus Res. 2026;21:200337.
    

    >> Share

    
    

    
    Turk J Pediatr

84. OZTURK YUZDEMIR K, User IR, Ozcan HN, Orhan D, et al
    Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach.
    Turk J Pediatr. 2025;67:920-926.
    

    >> Share

    
    

    
    Urologie

85. BOLENZ C, Zengerling F, Kubler H, Hahn O, et al
    [Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?].
    Urologie. 2026 Feb 6. doi: 10.1007/s00120-026-02774.
    

    >> Share

    
    

    
    Urology

86. SIGUENCIA F, Heard J, Smith SM, Pagano I, et al
    Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis.
    Urology. 2026 Feb 4:S0090-4295(26)00074-9. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share